Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.

10 Aug 2011

Hydros-TA therapy provides next generation of osteoarthritis relief

Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects.

10 Aug 2011

Common culinary spice derivative could treat tendinitis

A derivative of a common culinary spice found in Indian curries could offer a new treatment hope for sufferers of the painful condition tendinitis, an international team of researchers has shown.

9 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Exactech's new Optetrak Logic knee implant effective for painful arthritis

Kevin Hindle, a 47-year-old manufacturing engineer at Exactech, Inc., a global orthopaedic device company, regained his active lifestyle with an innovative new knee implant that he helped develop.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

New edition of ACOEM's Occupational Medicine Practice Guidelines released

Meniscal tears of the knee (aka, torn cartilage) are extraordinarily prevalent and become universally present as one ages. Treatment often involves surgery, but is surgery the best option? Not necessarily according to scientific evidence presented in the newly published 3rd edition of the American College of Occupational and Environmental Medicine's Occupational Medicine Practice Guidelines, knee disorders chapter.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Osiris second quarter revenues increase to $10.4 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the second quarter ended June 30, 2011.

5 Aug 2011

Higher levels of B cells make women more prone to autoimmune diseases

Researchers at National Jewish Health have discovered a type of cell that may contribute to autoimmune disease and suggests why diseases such as lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently than men. The cells, a subset of immune-system B cells, make autoantibodies, which bind to and attack the body's own tissue.

5 Aug 2011

Positive results from Antares Pharma VIBEX MTX clinical study on RA

Antares Pharma, Inc. today announced the positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate (MTX) for the treatment of rheumatoid arthritis.

5 Aug 2011

Positive results from hGH-CTP Phase II trial in growth hormone deficient adults

PROLOR Biotech, Inc. today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.

4 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Knee osteoarthritis more common in women than men

A Mayo Clinic orthopedic surgeon suspects that the nagging pain and inflammation that women can experience in their knees may be different from what men encounter, and she has been chosen to lead a novel U.S.-Canadian study to explore the question.

4 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011

Rigel reports net loss of $21.5 million for second quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2011.

2 Aug 2011

Lesser toe deformities should be treated early: Literature review

While deformities of the lesser toes can be very painful, there are numerous surgical and nonsurgical treatments for these conditions that are usually quite effective.

2 Aug 2011

NYU Langone receives NHLBI grant for comparative effectiveness ISCHEMIA Trial

NYU Langone Medical Center announced it has received an $84 million grant from the National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH), to study the comparative effectiveness of two initial management strategies for patients with coronary artery disease.

2 Aug 2011

RSS honors UNC researcher with 2011 Distinguished Service to Rural Life Award

Joanne M. Jordan, MD, MPH, director of the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill, has received the 2011 Distinguished Service to Rural Life Award from the Rural Sociological Society.

2 Aug 2011